| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Divisions of Experimental Oncology B [S. C. R., M. C., F. Z.], Experimental Oncology A [G. D. T., M. A. P., C. L.], Experimental Oncology E [S. M., F. O., M. I. C.], Pathological Anatomy [S. P.], and Gynecological Oncology [S. O., S. B., G. L. B., G. S.], Istituto Nazionale Tumori, 20133 Milan, Italy
The p53 protein is a multifunctional transcriptional regulator involved in cellular response to DNA damage and has been implicated as a putative determinant of sensitivity of tumor cells to cytotoxic agents. Since the p53 gene becomes inactivated in over one-half of advanced ovarian carcinoma, in this study we have examined the relationships between p53 gene alterations, p53 immunoreactivity, and response to cisplatin-based chemotherapy in ovarian cancer patients. All patients had advanced (FIGO stage III or IV) overian carcinoma and, with one exception, were untreated at the time of collection of tumor specimens. After initial debulking surgery, patients received high-dose cisplatin therapy. Tumor samples were analyzed for p53 gene mutations and for p53 protein accumulation, and the findings were correlated with tumor responsiveness. Of the 33 tumors examined, p53 gene mutations were found in 20 cases, including 15 missense mutations, 2 deletions, 2 nonsense mutations, and a base substitution at splice site. Twenty tumors showed positive immunostaining for p53. Only missense mutations were associated with positive immunostaining. In addition, p53 overexpression was detected in five tumors in the absence of mutations. Most (12 of 14) of the missense mutations associated with p53 protein stabilization were found refractory to therapy, as well as tumors overexpressing wild-type p53 (4 of 5). A significant correlation has been found between p53 accumulation, type of mutation (i.e., missense mutations), and pathological response to cisplatin-based therapy. In conclusion, the present results are consistent with a role of p53 as a determinant of chemosensitivity of ovarian carcinoma.
1 This work was partially supported by grants from the Consiglio Nazionale delle Ricerche (Finalized Project "Applicazioni Cliniche della Ricerca Oncologica"), the Associazione Italiana per la Ricerca sul Cancro, and the Ministero della Sania'.
2 To whom requests for reprints should be addressed, at the Division of Experimental Oncology B. Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: +30-2-2390267; Fax: +39-2-2390764.
Received 11/13/95. Accepted 1/ 2/96.
This article has been cited by other articles:
|
|
 |
|
  A. A. Dar, A. Belkhiri, J. Ecsedy, A. Zaika, and W. El-Rifai Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells Cancer Res., November 1, 2008; 68(21): 8998 - 9004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Itamochi, J. Kigawa, Y. Kanamori, T. Oishi, C. Bartholomeusz, R. Nahta, F. J. Esteva, N. Sneige, N. Terakawa, and N. T. Ueno Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy Mol. Cancer Ther., January 1, 2007; 6(1): 227 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Licitra, S. Suardi, P. Bossi, L.D. Locati, L. Mariani, P. Quattrone, S. Lo Vullo, M. Oggionni, P. Olmi, G. Cantu, et al. Prediction of TP53 Status for Primary Cisplatin, Fluorouracil, and Leucovorin Chemotherapy in Ethmoid Sinus Intestinal-Type Adenocarcinoma J. Clin. Oncol., December 15, 2004; 22(24): 4901 - 4906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mezzanzanica, E. Balladore, F. Turatti, E. Luison, P. Alberti, M. Bagnoli, M. Figini, A. Mazzoni, F. Raspagliesi, M. Oggionni, et al. CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma Clin. Cancer Res., August 1, 2004; 10(15): 5202 - 5214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Havrilesky, K. M. Darcy, H. Hamdan, R. L. Priore, J. Leon, J. Bell, and A. Berchuck Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., October 15, 2003; 21(20): 3814 - 3825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Buttitta, C. Pellegrini, A. Marchetti, A. Gadducci, S. Cosio, L. Felicioni, F. Barassi, S. Salvatore, C. Martella, G. Coggi, et al. Human Telomerase Reverse Transcriptase mRNA Expression Assessed by Real-Time Reverse Transcription Polymerase Chain Reaction Predicts Chemosensitivity in Patients With Ovarian Carcinoma J. Clin. Oncol., April 1, 2003; 21(7): 1320 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Briz, R. I. R. Macias, M. Vallejo, A. Silva, M. A. Serrano, and J. J. G. Marin Usefulness of Liposomes Loaded with Cytostatic Bile Acid Derivatives to Circumvent Chemotherapy Resistance of Enterohepatic Tumors Mol. Pharmacol., March 1, 2003; 63(3): 742 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sultana, J. Kigawa, Y. Kanamori, H. Itamochi, T. Oishi, S. Sato, S. Kamazawa, M. Ohwada, M. Suzuki, and N. Terakawa Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer Ann. Onc., February 1, 2003; 14(2): 214 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shoji, F. Tanaka, T. Takata, K. Yanagihara, Y. Otake, N. Hanaoka, R. Miyahara, T. Nakagawa, Y. Kawano, S. Ishikawa, et al. Clinical Significance of p21 Expression in Non-Small-Cell Lung Cancer J. Clin. Oncol., September 15, 2002; 20(18): 3865 - 3871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Reles, W. H. Wen, A. Schmider, C. Gee, I. B. Runnebaum, U. Kilian, L. A. Jones, A. El-Naggar, C. Minguillon, I. Schonborn, et al. Correlation of p53 Mutations with Resistance to Platinum-based Chemotherapy and Shortened Survival in Ovarian Cancer Clin. Cancer Res., October 1, 2001; 7(10): 2984 - 2997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Calogero, A. Arcella, G. De Gregorio, A. Porcellini, D. Mercola, C. Liu, V. Lombari, M. Zani, G. Giannini, F. M. Gagliardi, et al. The Early Growth Response Gene EGR-1 Behaves as a Suppressor Gene That Is Down-Regulated Independent of ARF/Mdm2 but not p53 Alterations in Fresh Human Gliomas Clin. Cancer Res., September 1, 2001; 7(9): 2788 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Geisler, P. E. Lønning, T. Aas, H. Johnsen, O. Fluge, D. F. Haugen, J. R. Lillehaug, L. A. Akslen, and A.-L. Børresen-Dale Influence of TP53 Gene Alterations and c-erbB-2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer Cancer Res., March 1, 2001; 61(6): 2505 - 2512. [Abstract] [Full Text]
|
|
|
|
|
|
C. Lavarino, S. Pilotti, M. Oggionni, L. Gatti, P. Perego, G. Bresciani, M. A. Pierotti, G. Scambia, G. Ferrandina, A. Fagotti, et al. p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma J. Clin. Oncol., December 1, 2000; 18(23): 3936 - 3945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sigal and V. Rotter Oncogenic Mutations of the p53 Tumor Suppressor: The Demons of the Guardian of the Genome Cancer Res., December 1, 2000; 60(24): 6788 - 6793. [Abstract] [Full Text]
|
|
|
|
|
|
C. Heise, M. Lemmon, and D. Kirn Efficacy with a Replication-selective Adenovirus Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration Clin. Cancer Res., December 1, 2000; 6(12): 4908 - 4914. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Levesque, D. Katsaros, M. Massobrio, F. Genta, H. Yu, G. Richiardi, S. Fracchioli, A. Durando, R. Arisio, and E. P. Diamandis Evidence for a Dose-Response Effect between p53 (but not p21WAF1/Cip1) Protein Concentrations, Survival, and Responsiveness in Patients with Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy Clin. Cancer Res., August 1, 2000; 6(8): 3260 - 3270. [Abstract] [Full Text]
|
|
|
|
 |
|
 C.-T. Yang, L. You, C.-C. Yeh, J. W.-C. Chang, F. Zhang, F. McCormick, and D. M. Jablons Adenovirus-Mediated p14ARF Gene Transfer in Human Mesothelioma Cells J Natl Cancer Inst, April 19, 2000; 92(8): 636 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shiga, E. I. Heath, A. A. Rasmussen, B. Trock, P. G. Johnston, A. A. Forastiere, M. Langmacher, A. Baylor, M. Lee, and K. J. Cullen Prognostic Value of p53, Glutathione S-Transferase {{pi}}, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer Clin. Cancer Res., December 1, 1999; 5(12): 4097 - 4104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baekelandt, G. B. Kristensen, J. M. Nesland, C. G. Trope, and R. Holm Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian Cancer J. Clin. Oncol., July 1, 1999; 17(7): 2061 - 2061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Righetti, P. Perego, E. Corna, M. A. Pierotti, and F. Zunino Emergence of p53 Mutant Cisplatin-resistant Ovarian Carcinoma Cells following Drug Exposure:Spontaneously Mutant Selection Cell Growth Differ., July 1, 1999; 10(7): 473 - 478. [Abstract] [Full Text]
|
|
|
|
|
|
G. S. Hagopian, G. B. Mills, A. R. Khokhar, R. C. Bast Jr., and Z. H. Siddik Expression of p53 in Cisplatin-resistant Ovarian Cancer Cell Lines: Modulation with the Novel Platinum Analogue (1R, 2R-Diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV) Clin. Cancer Res., March 1, 1999; 5(3): 655 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cremonesi, P. Carrera, A. Fumagalli, S. Lucchiari, E. Cardillo, M. Ferrari, S. C. Righetti, F. Zunino, P. G. Righetti, and C. Gelfi Validation of Double Gradient Denaturing Gradient Gel Electrophoresis through Multigenic Retrospective Analysis Clin. Chem., January 1, 1999; 45(1): 35 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Zamble, T. Jacks, and S. J. Lippard p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells PNAS, May 26, 1998; 95(11): 6163 - 6168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. McCurrach, T. M. F. Connor, C. M. Knudson, S. J. Korsmeyer, and S. W. Lowe bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis PNAS, March 18, 1997; 94(6): 2345 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Bischoff, D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, et al. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells Science, October 18, 1996; 274(5286): 373 - 376. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
